Company Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally.
The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023.
The company was founded in 2017 and is based in Zug, Switzerland.
| Country | Switzerland |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Riad Sherif |
Contact Details
Address: Bahnhofstrasse 20 Zug, 6300 Switzerland | |
| Phone | 41 41 711 3960 |
| Website | oculis.com |
Stock Details
| Ticker Symbol | OCSAW |
| Exchange | NASDAQ |
| Stock Type | Warrants |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH1246223429 |
Key Executives
| Name | Position |
|---|---|
| Riad Sherif | Chief Executive Officer |
| Sylvia Cheung | Chief Financial Officer |